Equine Encephalitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecul